TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer

References

• Key Statistics for Prostate Cancer. www.cancer.org/cancer/prostate-cancer/about/key-statistics.html (12 September 2022).
   Google Scholar
• Prostate Cancer Statistics. www.wcrf.org/cancer-trends/prostate-cancer-statistics/ (21 September 2022).
   Google Scholar
• Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race/ethnicity - United States, 2001-2017. MMWR Morb. Mortal. Wkly Rep. 69(41), 1473–1480 (2020).
   PubMed Web of Science ®Google Scholar
• Pinsky PF, Black A, Daugherty SE et al. Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer 125(17), 2965–2974 (2019).
   PubMed Web of Science ®Google Scholar
• Greenberg DC, Wright KA, Lophathanon A, Muir KR, Gnanapragasam VJ. Changing presentation of prostate cancer in a UK population--10 year trends in prostate cancer risk profiles in the East of England. Br. J. Cancer 109(8), 2115–2120 (2013).
   PubMed Web of Science ®Google Scholar
• Thurin NH, Rouyer M, Gross-Goupil M et al. Epidemiology of metastatic castration-resistant prostate cancer: a first estimate of incidence and prevalence using the French nationwide healthcare database. Cancer Epidemiol. 69, DOI:10.1016/j.canep.2020.101833 (2020).
   PubMed Web of Science ®Google Scholar
• Chen R, Ren S, Yiu MK et al. Prostate cancer in Asia: a collaborative report. Asian J. Urol. 1(1), 15–29 (2014).
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J. Clin. 71(1), 7–33 (2021).
   PubMed Web of Science ®Google Scholar
• Harada K, Shiota M, Minato A et al. Treatment strategies for metastatic castration-sensitive prostate cancer: from “all-comers” to “personalized” approach. Onco. Targets Ther. 14, 2967–2974 (2021).
   PubMed Web of Science ®Google Scholar
• Blas L, Shiota M, Eto M. Current status and future perspective on the management of metastatic castration-sensitive prostate cancer. Cancer Treat. Res. Commun. 32, DOI:10.1016/j.ctarc.2022.100606 (2022).
   PubMedGoogle Scholar
• Freedland SJ, Sandin R, Sah J et al. Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration. Cancer Med. 10(23), 8570–8580 (2021).
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Chen YH, Carducci MA et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized Phase III E3805 CHAARTED trial. J. Clin. Oncol. 36(11), 1080–1087 (2018).
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Azad AA, Iguchi T et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 40(15), 1616–1622 (2022).
   PubMed Web of Science ®Google Scholar
• Chi KN, Chowdhury S, Bjartell A et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, Phase III TITAN study. J. Clin. Oncol. 39(20), 2294–2303 (2021).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 20(5), 686–700 (2019).
   PubMed Web of Science ®Google Scholar
• Chi KN, Agarwal N, Bjartell A et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381(1), 13–24 (2019).
   PubMed Web of Science ®Google Scholar
• Hahn AW, Higano CS, Taplin M-E, Ryan CJ, Agarwal N. Metastatic castration-sensitive prostate cancer: optimizing patient selection and treatment. Am. Soc. Clin. Oncol. Educ. Book. 38, 363–371 (2018).
   PubMedGoogle Scholar
• Parker C, Castro E, Fizazi K et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(9), 1119–1134 (2020).
   PubMed Web of Science ®Google Scholar
• Chung JH, Dewal N, Sokol E et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis. Oncol. 3, DOI:10.1200/PO.18.00283 (2019).
   Web of Science ®Google Scholar
• Armenia J, Wankowicz SAM, Liu D et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50(5), 645–651 (2018).
   PubMed Web of Science ®Google Scholar
• Castro E, Romero-Laorden N, Del Pozo A et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 37(6), 490–503 (2019).
   PubMed Web of Science ®Google Scholar
• Annala M, Vandekerkhove G, Khalaf D et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 8(4), 444–457 (2018).
   PubMed Web of Science ®Google Scholar
• Vandekerkhove G, Struss WJ, Annala M et al. Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer. Eur. Urol. 75(4), 667–675 (2019).
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science 355(6330), 1152–1158 (2017).
   PubMed Web of Science ®Google Scholar
• Turk AA, Wisinski KB. PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer 124(12), 2498–2506 (2018).
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035), 913–917 (2005).
   PubMed Web of Science ®Google Scholar
• Shen Y, Rehman FL, Feng Y et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin. Cancer Res. 19(18), 5003–5015 (2013).
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Renaud A et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 13(2), 433–443 (2014).
   PubMed Web of Science ®Google Scholar
• Agarwal N, Azad A, Shore ND et al. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 Phase III study design. Future Oncol. 18(4), 425–436 (2022).
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SN, Das BB et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72(21), 5588–5599 (2012).
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. TALZENNA® (talazoparib) prescribing information. (June 2023).
   Google Scholar
• Agarwal N, Azad AA, Carles J et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402, 291–303 (2023).
   PubMed Web of Science ®Google Scholar
• de Bono JS, Mehra N, Scagliotti GV et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol. 22(9), 1250–1264 (2021).
   PubMed Web of Science ®Google Scholar
• Feng Q, He B. Androgen receptor signaling in the development of castration-resistant prostate cancer. Front. Oncol. 9, 858 (2019).
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP et al. ARCHES: a randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37(32), 2974–2986 (2019).
   PubMed Web of Science ®Google Scholar
• Smith MR, Hussain M, Saad F et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl. J. Med. 386(12), 1132–1142 (2022).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377(4), 352–360 (2017).
   PubMed Web of Science ®Google Scholar
• James ND, de Bono JS, Spears MR et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377(4), 338–351 (2017).
   PubMed Web of Science ®Google Scholar
• Schiewer MJ, Goodwin JF, Han S et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2(12), 1134–1149 (2012).
   PubMed Web of Science ®Google Scholar
• Polkinghorn WR, Parker JS, Lee MX et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 3(11), 1245–1253 (2013).
   PubMed Web of Science ®Google Scholar
• Li L, Karanika S, Yang G et al. Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci. Signal. 10(480), eaam7479 (2017).
   PubMed Web of Science ®Google Scholar
• Min A, Jang H, Kim S et al. Androgen receptor inhibitor enhances the antitumor effect of PARP inhibitor in breast cancer cells by modulating DNA damage response. Mol. Cancer Ther. 17(12), 2507–2518 (2018).
   PubMed Web of Science ®Google Scholar
• Chakraborty G, Armenia J, Mazzu YZ et al. Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression. Clin. Cancer Res. 26(8), 2047–2064 (2020).
   PubMed Web of Science ®Google Scholar
• Agarwal N, Zhang T, Efstathiou E et al. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. Eur. J. Cancer 192, DOI:10.1016/j.ejca.2023.113249 (2023).
   PubMed Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382(22), 2091–2102 (2020).
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration . LYNPARZA® (olaparib) prescribing information. ( Revised May 2023).
   Google Scholar
• LYNPARZA® (olaparib) Summary of Product Characteristics. www.medicines.org.uk/emc/product/9204/smpc (14 May 2021).
   Google Scholar
• Abida W, Patnaik A, Campbell D et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol. 38(32), 3763–3772 (2020).
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration . RUBRACA® (rucaparib) prescribing information. ( Revised June 2022).
   Google Scholar
• Asim M, Tarish F, Zecchini HI et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat. Commun. 8(1), 374 (2017).
   PubMedGoogle Scholar
• Gui B, Gui F, Takai T et al. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proc. Natl Acad. Sci. USA 116(29), 14573–14582 (2019).
   PubMed Web of Science ®Google Scholar
• Chi KN, Rathkopf D, Smith MR et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J. Clin. Oncol. 41(18), 3339–3351 (2023).
   PubMed Web of Science ®Google Scholar
• Clarke NW, Armstrong AJ, Thiery-Vuillemin A et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 1(9), DOI:10.1056/EVIDoa2200043 (2022).
   PubMedGoogle Scholar
• Talazoparib + enzalutamide vs. enzalutamide monotherapy in mCRPC (TALAPRO-2) (NCT03395197). https://clinicaltrials.gov/ct2/show/NCT03395197 (23 February 2023).
   Google Scholar